And that viewpoint re prelinical trials is actually pretty valid in most cases. But RAC is not like most biotechs. I think holders are extremely pumped because holders like @Mason14 are able to situate the preclinical results and contemporary discoveries within RAC's historical performance data in humans - of which there is a lot, to extrapolate the promise of the drug and how future trials may play out.
Meanwhile the market thinks we are "just preclinical" or that we just have an old chemotherapeutic drug.
And that viewpoint re prelinical trials is actually pretty valid...
-
- There are more pages in this discussion • 9,925 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.54 |
Change
-0.015(0.97%) |
Mkt cap ! $261.5M | |||
| Open | High | Low | Value | Volume |
| $1.55 | $1.55 | $1.50 | $111.4K | 73.35K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 500 | $1.53 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.56 | 1400 | 1 |
View Market Depth
| Last trade - 16.10pm 02/08/2024 (20 minute delay) ? |
| RAC (ASX) Chart |